BCR
ENSG00000186716
Target class
Other cytosolic protein
Chromosome
22
Approved drugs
7
Clinical candidates (approved and in development)
10
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- BCR
- Gene name
- BCR activator of RhoGEF and GTPase
- Gene symbol
- BCR
- Protein name
- Breakpoint cluster region protein (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-26)
- D22S662
- CML
- PHL
- ALL
- D22S11
- BCR1
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing|Dbl family Rho GEFs|C2 domain containing|My-T-BRC complex
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 46.94
- Tissue specificity (Gini)
- 0.253
- Tissue specificity (tau)
- 0.589
- KEGG gene identifiers
- hsa:613
- Protein interaction confidence
- 0.846455
- Protein interaction partners
- 22
- R-HSA-1839117
- R-HSA-5655302
- R-HSA-8980692
- R-HSA-9013026
- R-HSA-9013106
- R-HSA-9013148
- R-HSA-9013149
- R-HSA-9013404
- R-HSA-9013423
- End position
- 23318037
- Start position
- 23179704
- Chromosome
- 22
- Strand
- Forward
- Postsynaptic density . Cell projection, dendritic spine . Cell projection, axon . Synapse .
- Cytosol
- Nucleoplasm
- Plasma membrane
- Tissue specificity (tau)
- 0.58874
- Expression inequality (Gini)
- 0.253316
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 46.94
- Brain - Caudate (basal ganglia)
- 42.9
- Nerve - Tibial
- 35.06
- Brain - Putamen (basal ganglia)
- 33.78
- Pituitary
- 31.78
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)46.94
- Brain - Caudate (basal ganglia)42.9
- Nerve - Tibial35.06
- Brain - Putamen (basal ganglia)33.78
- Pituitary31.78
- Thyroid31.52
- Brain - Cortex29.27
- Artery - Tibial28.94
- Artery - Aorta27.65
- Brain - Frontal Cortex (BA9)27.35
- Lung26.97
- Brain - Anterior cingulate cortex (BA24)26.9
- Skin - Sun Exposed (Lower leg)26.58
- Brain - Cerebellum24.74
- Adipose - Subcutaneous23.88
- Esophagus - Mucosa23.6
- Artery - Coronary23.39
- Skin - Not Sun Exposed (Suprapubic)22.84
- Brain - Amygdala22.55
- Breast - Mammary Tissue22.03
- Adipose - Visceral (Omentum)21.71
- Brain - Cerebellar Hemisphere21.4
- Fallopian Tube21.34
- Kidney - Medulla20.72
- Brain - Hippocampus20.53
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007165
- GO:0007264
- GO:0030216
- GO:0035023
- GO:0048041
- GO:0051056
- GO:0090630
- GO:0005829
- GO:0016020
- GO:0032991
- GO:0070062
- GO:0004674
- GO:0004713
- GO:0005085
- GO:0005096
- GO:0005515
- GO:0106310
Related records
Trials (1,122)
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
- A Bioequivalence Study of Dasatinib Tablet
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
- A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin
- A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
- A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
- A Global Imatinib and Nilotinib Pregnancy Exposure Registry
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
- A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Drugs (15)
- Asciminib Bcr/Abl fusion protein inhibitor
- Asciminib hydrochloride Bcr/Abl fusion protein inhibitor
- Bosutinib Bcr/Abl fusion protein inhibitor
- Bosutinib monohydrate Bcr/Abl fusion protein inhibitor
- Dasatinib Bcr/Abl fusion protein inhibitor
- Dasatinib anhydrous Bcr/Abl fusion protein inhibitor
- Imatinib Bcr/Abl fusion protein inhibitor
- Imatinib mesylate Bcr/Abl fusion protein inhibitor
- Nilotinib Bcr/Abl fusion protein inhibitor
- Nilotinib hydrochloride monohydrate Bcr/Abl fusion protein inhibitor
- Olverembatinib Bcr/Abl fusion protein inhibitor
- Ponatinib Bcr/Abl fusion protein inhibitor
- Ponatinib hydrochloride Bcr/Abl fusion protein inhibitor
- Radotinib Bcr/Abl fusion protein inhibitor
- Vodobatinib Bcr/Abl fusion protein inhibitor